What determines P2RY12 receptor expression/activity specifically in VSMCs during atherosclerosis progression?

PARTIALLY ADDRESSED

The study shows P2RY12 regulates VSMC foam cell formation but doesn't explain what controls P2RY12 expression or activation in VSMCs during disease progression. Understanding these upstream regulators could reveal new therapeutic targets for vascular neurodegeneration. Gap type: unexplained_observation Source paper: The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. (2021, Autophagy, PMID:32160082)

Priority: 0.80 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: What determines P2RY12 receptor expression/activity specifically in VSMCs during atherosclerosis progression? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What determines P2RY12 receptor expression/activity specifically in VSMCs during atherosclerosis progression? — INVOKE-2 (completed)

📈 Living Dashboards

0

Hypotheses

0.000

Top Score

0.000

Avg Score

0

Debates

0.00

Avg Quality

60%

Resolution

0

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (4)

P2RY12→VSMC foam cell formationP2RY12→PI3K-AKTP2RY12→MTORP2RY12→lipid accumulation

associated with (4)

P2RY12→Homeostatic MicrogliaP2RY12→SQSTM1P2RY12→AlsP2RY12→Alzheimer's_disease

biomarker for (1)

P2RY12→Microglia

causes (2)

P2RY12→VSMC foam cell formationMICROGLIA→P2RY12

contributes to (1)

P2RY12→clopidogrel resistance

data in (1)

ds-f2c28aed24a7→P2RY12

disrupts (1)

expressed in (7)

MICROGLIA→P2RY12P2RY12→microgliaMACROPHAGE→P2RY12P2RY12→DAM microgliaAPOE→P2RY12

▸ Show 2 more

P2RY12→middle_temporal_gyrus_spiny_L5P2RY12→middle_temporal_gyrus_spiny_L3

inhibits (8)

P2RY12→autophagyP2RY12→LC3P2RY12→SQSTM1P2RY12→autophagy pathwayP2RY12→Cholesterol Efflux

▸ Show 3 more

P2RY12→APOEP2RY12→PYROPTOSISP2RX7→P2RY12

involved in (1)

P2RY12→purinergic signaling

markers (1)

participates in (1)

P2RY12→purinergic signaling

prevents (1)

P2RY12→tufted astrocyte formation

promotes (2)

P2RY12→Vsmc-Derived Foam Cell FormationP2RY12→VSMC-derived foam cell formation

protects against (1)

provides data for (1)

P2RY12→ds-f2c28aed24a7

regulates (7)

P2RY12→platelet aggregationP2RY12→microglia activationP2RY12→microglial_process_motilityP2RY12→MICROGLIAL PHAGOCYTIC ACTIVITYP2RY12→TAU

▸ Show 2 more

P2RY12→foam cell formationP2RY12→autophagy

stabilizes (2)

MACROPHAGE→P2RY12P2RY12→TAU

targets (2)

h-f99ce4ca→P2RY12h-5daecb6e→P2RY12

treats (1)

MICROGLIA→P2RY12

upregulates (1)

P2RY12→UPREGULATES

🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps